Gaxos published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025. Revenue was USD 1.93 million, including USD 1.51 million from RNK Health administrative services and USD 421,995 from subscriptions. Net loss was USD 4.28 million, compared with a 25.1% wider loss a year earlier. Operating expenses rose 84.7% to USD 6.85 million, driven by advertising and marketing expense of USD 3.08 million, which the company attributed primarily to increased marketing of RNK Health services and Gaxos Labs subscription services. Gaxos ended the year with cash of USD 840,799, short-term investments of USD 11.35 million and working capital of USD 11.92 million, and said it expects existing working capital and cash to be sufficient for the next 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gaxos.ai Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-029223), on March 17, 2026, and is solely responsible for the information contained therein.